



## PRESCRIBING JARDIANCE FOR ADULTS WITH ESTABLISHED CV DISEASE AND TYPE 2 DIABETES

# A CARDIOLOGIST'S REFERENCE GUIDE

### INDICATIONS AND LIMITATIONS OF USE

JARDIANCE is indicated to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV disease.

JARDIANCE is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

JARDIANCE is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

### IMPORTANT SAFETY INFORMATION

**CONTRAINDICATIONS:** History of serious hypersensitivity to empagliflozin or any of the excipients in JARDIANCE; severe renal impairment, end-stage renal disease, or dialysis.

CV=cardiovascular.

Please see additional Important Safety Information on the following pages.  
Please see JARDIANCE [Prescribing Information](#) and [Medication Guide](#).

**Jardiance**<sup>®</sup>   
(empagliflozin) tablets  
10 mg/25 mg



## Cardiologists have initiated JARDIANCE more than any other medication in its class\*

Leading cardiologists nationwide are doing more to reduce the risk of CV death for their adult patients with established CV disease and type 2 diabetes by prescribing JARDIANCE. See how you can join them by initiating JARDIANCE for your patients. JARDIANCE is the first oral treatment in its class indicated to reduce the risk of CV death for adults with established CV disease and type 2 diabetes.

\*As measured by NBRx for the 26 weeks ending January 25, 2019.



## Identifying patients in your practice



**JARDIANCE is indicated for adults with established cardiovascular disease and type 2 diabetes**

CV disease includes coronary artery disease, peripheral artery disease, or a history of myocardial infarction or stroke



**Do not use JARDIANCE for:**

- Patients with type 1 diabetes
- Treatment of diabetic ketoacidosis

**JARDIANCE is contraindicated in patients with:**

- A history of serious hypersensitivity to empagliflozin or any of the excipients in JARDIANCE
- Severe renal impairment
- End-stage renal disease
- Dialysis

### IMPORTANT SAFETY INFORMATION (continued)

#### WARNINGS AND PRECAUTIONS

**Hypotension:** Empagliflozin causes intravascular volume contraction and symptomatic hypotension may occur. Before initiating JARDIANCE, assess and correct volume status in the elderly, and in patients with renal impairment, low systolic blood pressure, or on diuretics. Monitor for hypotension.

**Ketoacidosis:** Ketoacidosis, a serious life-threatening condition requiring urgent hospitalization, has been identified in patients with type 1 and type 2 diabetes mellitus receiving SGLT2 inhibitors, including empagliflozin. Fatal cases of ketoacidosis have been reported in patients taking empagliflozin. Patients who present with signs and symptoms of metabolic acidosis should be assessed for ketoacidosis, even if blood glucose levels are less than 250 mg/dL. If suspected, discontinue JARDIANCE, evaluate, and treat promptly. Before initiating JARDIANCE, consider risk factors for ketoacidosis. Patients may require monitoring and temporary discontinuation in situations known to predispose to ketoacidosis.

Please see additional Important Safety Information on the following pages.  
Please see JARDIANCE [Prescribing Information](#) and [Medication Guide](#).

**Jardiance**<sup>®</sup>   
(empagliflozin) tablets  
10 mg/25 mg



## Usage considerations with type 2 diabetes medications

### JARDIANCE CAN BE PRESCRIBED ON TOP OF CV AND T2D STANDARD-OF-CARE MEDICATIONS

In addition to their CV treatment, your patients may be taking type 2 diabetes (T2D) medications such as:

- Metformin
- Thiazolidinedione (TZD)
- DPP-4 inhibitor (DPP-4)
- GLP-1 agonist (GLP-1)
- Insulin (may require titration)
- Sulfonylurea (SU) (may require titration)

**JARDIANCE demonstrated hypoglycemia rates similar to placebo when used as monotherapy or add-on to metformin**

### A GREAT PLACE TO START: PRESCRIBE JARDIANCE TO YOUR PATIENTS ON METFORMIN

|   | Placebo | JARDIANCE 10 mg |
|---|---------|-----------------|
| <b>Monotherapy*</b>                                       |         |                 |
| Overall (plasma glucose $\leq$ 70 mg/dL)                  | 0.4%    | <b>0.4%</b>     |
| Severe (requiring assistance regardless of blood glucose) | 0%      | <b>0%</b>       |
| <b>Add-on to metformin**</b>                              |         |                 |
| Overall (plasma glucose $\leq$ 70 mg/dL)                  | 0.5%    | <b>1.8%</b>     |
| Severe (requiring assistance regardless of blood glucose) | 0%      | <b>0%</b>       |

**Hypoglycemia rates were higher when JARDIANCE was used in combination with sulfonylurea or insulin**

- A lower dose of insulin or insulin secretagogues (eg, sulfonylureas) may be required to reduce the risk of hypoglycemia when JARDIANCE is used in combination with these agents

\*At 24 weeks. Placebo (n=229), JARDIANCE (n=224)

\*\*At 24 weeks. Placebo (n=206), JARDIANCE (n=217)

### IMPORTANT SAFETY INFORMATION (continued)

#### WARNINGS AND PRECAUTIONS (continued)

**Acute Kidney Injury and Impairment in Renal Function:** Empagliflozin causes intravascular volume contraction and can cause renal impairment. Acute kidney injury requiring hospitalization and dialysis have been identified in patients taking SGLT2 inhibitors, including empagliflozin; some reports involved patients younger than 65 years of age. Before initiating JARDIANCE, consider factors that may predispose patients to acute kidney injury. Consider temporary discontinuation in settings of reduced oral intake or fluid losses. Monitor patients for signs and symptoms of acute kidney injury. If it occurs, discontinue JARDIANCE and treat promptly.

Empagliflozin increases serum creatinine and decreases eGFR. Patients with hypovolemia may be more susceptible to these changes. Before initiating JARDIANCE, evaluate renal function and monitor thereafter. More frequent monitoring is recommended in patients with eGFR  $<$ 60 mL/min/1.73 m<sup>2</sup>. Discontinue JARDIANCE in patients with a persistent eGFR  $<$ 45 mL/min/1.73 m<sup>2</sup>.

Please see additional Important Safety Information on the following pages.  
Please see JARDIANCE [Prescribing Information](#) and [Medication Guide](#).

**Jardiance**   
(empagliflozin) tablets  
10 mg/25 mg

10 mg

## Dosing and administration

### One pill, once daily

- The recommended dose for JARDIANCE is one **10 mg** pill once daily
- JARDIANCE can be taken with or without food in the morning



## Patient support



### Access

- Lowest branded copay\* for most commercially insured patients – More coverage. Fewer callbacks



### Affordability

- \$0 Patient Copay Card available for eligible patients†



### Patient Support Resources

- Free access to disease education
- Online compliance reminders

### ASK YOUR REPRESENTATIVE ABOUT JARDIANCE SUPPORT RESOURCES FOR YOUR PATIENTS

\*Source: Fingertip Formulary, health plan or state listed above, and/or data on file, Boehringer Ingelheim Pharmaceuticals, Inc. as of 1/1/2019. Placement on formulary does not establish clinical comparability of products, including safety and efficacy, and is not a guarantee of full or partial coverage and/or payment. Contact health plan, state, or [www.medicare.gov](http://www.medicare.gov) for most current information, as it may change without notice. This is not intended to be an exhaustive list of all plans in your area. Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC do not sponsor or endorse any particular plan, and the company/plan names listed do not imply their endorsement of Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC, or the product(s) referenced.

†Eligible patients 18 years or older may pay as little as \$0/month with a maximum savings up to \$250/ monthly prescription. Card valid for 12 consecutive months from activation date. Benefits not to exceed program expiration on December 31, 2019. If you live in Massachusetts, card expires on the earlier of June 30, 2019, or date AB-rated generic equivalent is available. One card per patient, not transferable, and cannot be combined with any other offer. Program not health insurance. Only valid for commercially insured patients in the 50 United States, DC, and Puerto Rico. **Not eligible if prescriptions are paid for in part/full by state or federally funded program(s)**, like Medicare Part D, Medicaid, Vet. Aff., Dept. of Def., or TRICARE and where prohibited by law. Offer may change at any time, without notice.

### IMPORTANT SAFETY INFORMATION (continued)

#### WARNINGS AND PRECAUTIONS (continued)

**Urosepsis and Pyelonephritis:** Serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization have been identified in patients receiving SGLT2 inhibitors, including empagliflozin. Treatment with SGLT2 inhibitors increases the risk for urinary tract infections. Evaluate for signs and symptoms of urinary tract infections and treat promptly.

**Hypoglycemia:** The use of JARDIANCE in combination with insulin or insulin secretagogues can increase the risk of hypoglycemia. A lower dose of insulin or the insulin secretagogue may be required.

Please see additional Important Safety Information on the following pages.  
Please see JARDIANCE [Prescribing Information](#) and [Medication Guide](#).

Jardiance®   
(empagliflozin) tablets  
10 mg/25 mg

# Join the growing number of cardiologists prescribing JARDIANCE\*

\*As measured by NBRx for the 26 weeks ending January 25, 2019.



## Getting Started with JARDIANCE

1. **Identify** appropriate adult patients with established CVD and T2D
2. **Initiate** JARDIANCE 10 mg once daily
3. **Inform** patients and their referral network that you prescribed JARDIANCE to reduce the risk of CV death

CVD=cardiovascular disease.

For more information, see your representative or go to [jardiancehcp.com](http://jardiancehcp.com)

### IMPORTANT SAFETY INFORMATION (continued)

#### WARNINGS AND PRECAUTIONS (continued)

**Necrotizing Fasciitis of the Perineum (Fournier's Gangrene):** Serious, life-threatening cases have occurred in both females and males. Assess patients presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise. If suspected, institute prompt treatment and discontinue JARDIANCE.

**Genital Mycotic Infections:** Empagliflozin increases the risk for genital mycotic infections, especially in patients with prior infections. Monitor and treat as appropriate.

**Hypersensitivity Reactions:** Discontinue JARDIANCE, treat promptly, and monitor until signs and symptoms resolve.

**Increased Low-Density Lipoprotein Cholesterol (LDL-C):** Monitor and treat as appropriate.

**MOST COMMON ADVERSE REACTIONS (≥5%):** Urinary tract infections and female genital mycotic infections.

**DRUG INTERACTIONS:** Coadministration with diuretics may enhance the potential for volume depletion.

#### USE IN SPECIAL POPULATIONS

**Pregnancy:** JARDIANCE is not recommended, especially during the second and third trimesters.

**Lactation:** JARDIANCE is not recommended while breastfeeding.

**Geriatric Use:** JARDIANCE is expected to have diminished efficacy in elderly patients with renal impairment. Renal function should be assessed more frequently in elderly patients. The incidence of volume depletion-related adverse reactions and urinary tract infections increased in patients ≥75 years treated with empagliflozin.

CL-JAR-100023 10.30.18

Please see additional Important Safety Information on the following pages.  
Please see JARDIANCE [Prescribing Information](#) and [Medication Guide](#).

**Jardiance**   
(empagliflozin) tablets  
10 mg/25 mg



---

**DO MORE TO REDUCE THE RISK OF CV DEATH:  
PRESCRIBE JARDIANCE ON TOP OF STANDARD OF CARE  
FOR ADULTS WITH ESTABLISHED CVD AND T2D**

---

#### **INDICATIONS AND LIMITATIONS OF USE**

JARDIANCE is indicated to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV disease.

JARDIANCE is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

JARDIANCE is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

#### **IMPORTANT SAFETY INFORMATION**

**CONTRAINDICATIONS:** History of serious hypersensitivity to empagliflozin or any of the excipients in JARDIANCE; severe renal impairment, end-stage renal disease, or dialysis.

Please see additional Important Safety Information on the preceding pages.  
Please see JARDIANCE [Prescribing Information](#) and [Medication Guide](#).

**Jardiance**<sup>®</sup>   
(empagliflozin) tablets  
10 mg/25 mg